Gilde Healthcare leads USD 20 million financing round of Belgian sleep therapy company Nyxoah - Gilde Healthcare

Gilde Healthcare leads USD 20 million financing round of Belgian sleep therapy company Nyxoah

July 7, 2016

Board will be strengthened with industry experts and Enrique Vega appointed as new CEO

Mont-Saint-Guibert, Belgium – Nyxoah S.A., a medical device company focused on developing a neurostimulation based, disruptive therapy for patients suffering from Obstructive Sleep Apnea (OSA), announced today it has raised €18 million ($20 million) in fresh capital. The financing was led by Gilde Healthcare. SRIW and all existing shareholders also participated in the round. The proceeds will be used to finance Nyxoah’s go-to-market strategy, including CE Mark approval and the US FDA approval process.

The company is pleased to announce the appointment of Enrique Vega as Chief Executive Officer as of September 1st 2016. Mr. Vega is an experienced senior executive with a successful track record in the Cardiac Rhythm Management, Sleep Apnea and Neurostimulation fields. Nyxoah’s board is now composed of:

  • Robert Taub (company co-founder) – Chairman,
  • Janke Dittmer (Partner at Gilde Healthcare) – Vice-Chairman,
  • Jürgen Hambrecht (former CEO of BASF) – Director,
  • Don Deyo (former VP Neuromodulation R&D at Medtronic) – Independent Director and
  • Kevin Rakin (experienced lifescience executive and investor) – Independent Director.

“In Western countries alone there are 5 million OSA patients who require treatment but have failed current gold standard therapy,” said Robert Taub, Nyxoah co-founder and CEO “this large unmet need can be addressed by Nyxoah’s bilateral neurostimulation therapy.”

 

About Nyxoah

Nyxoah S.A. is a medical device company, focused on developing and commercializing a disruptive neurostimulation based therapy for the treatment of Obstructive Sleep Apnea (OSA). Headquartered in Mont-Saint-Guibert, Nyxoah SA was co-founded in 2009 by Robert Taub.

The company has developed the first and only lead-free neurostimulator, capable of delivering bilateral hypoglossal nerve stimulation for moderate to severe OSA patients, who have failed conventional CPAP therapy.

About Gilde Healthcare

Gilde Healthcare (Utrecht, The Netherlands and Cambridge, USA) is a European specialist investment firm focused on private healthcare companies. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, medical devices, therapeutics and healthcare services. Gilde successfully builds healthcare businesses across Europe and US, investing up to €30 million in a single portfolio company. For a list of Gilde’s portfolio companies please visit the website at www.gildehealthcare.com.

Gilde Healthcare company Moximed reports treatment of first commercial patients post FDA approval

Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced the first commercial cases of the MISHA™ Knee System, an implantable shock absorber...
September 6, 2023

Gilde Healthcare company Withings launches its next-generation scanwatch with enhanced sensors to monitor additional health metrics 24/7

In 2014, Withings, a pioneer of the digital health movement, announced the world’s first hybrid watch. Today it furthers its leadership of the hybrid connected watch sector, unveiling the latest generation of its groundbreaking ScanWatch....
August 31, 2023

Gilde Healthcare company Big Health expands into adolescent mental health through acquisition of Limbix

Big Health, the leading provider of non-drug digital treatments for mental health, has acquired Limbix, creators of the first, evidence-based digital therapeutic for teens and young adults with symptoms of depression. Since its founding in...
July 17, 2023